Tyra Biosciences, Inc.
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- TYRATyra Biosciences, Inc0Calm
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Signing up patientsPhase 2285 patientsMain results: Oct 2030 - TYRATyra Biosciences, Inc0Calm
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Signing up patientsPhase 290 patientsMain results: Feb 2028 - TYRATyra Biosciences, Inc0Calm
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Running, no new patientsPhase 1/2310 patientsMain results: Nov 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 1 purchase
- Verjee RehanBoard member · Sep 9, 2026Bought 972 sharesabout $20 thousand ·
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.